The Motley Fool··Adria CiminoModerna Charts Post-Pandemic Course With Pipeline Diversification Strategy
Moderna shifts from pandemic revenues toward diversified pipeline including seasonal vaccines and oncology treatments, targeting cash breakeven by 2028 amid FDA progress on flu vaccine candidate.
MRNAFDA approvalmRNA technology